{"entity":{"id":"nct06368141","kind":"trial","name":"Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer","aka":["NeoCHIC"],"tldr":"A phase 2 trial of serplulimab, capecitabine and fOLFOX (5-FU, leucovorin, oxaliplatin) in colorectal cancer, run by Ruijin Hospital, now recruiting.","summary":"Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer is a phase 2, interventional study registered as NCT06368141 by Ruijin Hospital, with a registry enrolment figure of 56 participants, started 2024-05-01 and due to reach its primary completion in 2026-02-28. Interventions recorded: Serplulimab; Capecitabine; Oxaliplatin. Conditions listed: Colon Cancer. Primary outcome: pathologic complete response. Colorectal eligibility wording from the registry: \"* Patients with histopathological confirmed primary colon adenocarcinoma\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06368141","url":"https://clinicaltrials.gov/study/NCT06368141"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["colon-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["serplulimab","capecitabine","folfox"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06368141","phase":"2","setting":"Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer","sponsor":"Ruijin Hospital","enrolled":56,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06368141/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"},{"id":"serplulimab","kind":"drug","name":"Serplulimab","route":"/drugs/serplulimab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}